Silverarc Capital Management’s Cullinan Oncology CGEM Stock Holding History

Silverarc Capital Management’s Portfolio CGEM Stock Details CGEM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-265,032	Closed	-$2.71M	–	87
2023 Q1	$2.71M	Buy	265,032 +35,616	+16%	+$393K	1.12%	34
2022 Q4	$2.42M	Buy	229,416 +4,861	+2%	+$59K	0.69%	50
2022 Q3	$2.88M	Buy	224,555 +11,465	+5%	+$154K	0.97%	35
2022 Q2	$2.73M	Buy	+213,090	New	+$2.42M	0.84%	33
2021 Q3	–	Sell	-75,732	Closed	-$1.95M	–	89
2021 Q2	$1.95M	Buy	+75,732	New	+$2.33M	0.87%	41

Other funds holding CGEM

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

AIG

American International Group New York $2.93M AUM 12.08% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Silverarc Capital Management's CGEM Position: Q2 2023 in Review

Silverarc Capital Management sold out of Cullinan Oncology (CGEM) in Q2 2023, closing a stake of 265,032 shares — an estimated $2.71M sold.

Silverarc Capital Management first reported a position in CGEM in Q2 2021 and held it in 5 quarters. The position peaked at $2.88M in Q3 2022. 106 funds tracked by Wall St. Rank hold CGEM as of Q2 2023.

Silverarc Capital Management reported no remaining Cullinan Oncology position as of Q2 2023 after selling out during the quarter.
Silverarc Capital Management sold 265,032 Cullinan Oncology shares in Q2 2023, an estimated $2.71M.
Silverarc Capital Management first reported a position in Cullinan Oncology in Q2 2021 and held it in 5 quarters.
Silverarc Capital Management's Cullinan Oncology position peaked at $2.88M in Q3 2022.
106 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2023.

Based on Silverarc Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.